Last 30 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -25.16 | — | 5.11 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.93 | 70.39 | 2.94 | — | — | 80.17 | — | — | — | 147.94 | 50.35 | 93.25 | 21.07 |
| — | -12.2% | — | — | — | -45.8% | — | — | — | +172.1% | +875.1% | +309.1% | +121.7% | |
| P/B Ratio | 2.79 | 2.99 | 2.23 | 1.94 | 1.41 | 2.12 | 2.31 | 2.94 | 3.52 | 3.74 | 3.19 | 2.64 | 1.99 |
| — | +41.3% | -3.4% | -34.0% | -59.9% | -43.3% | -27.4% | +11.5% | +77.1% | +49.4% | +91.6% | +33.0% | +33.0% | |
| P/FCF | — | — | 4.29 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 4.95 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 4.55 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
IDEAYA Biosciences, Inc.'s operating margin was -869.5% in Q4 2025, down 921.7 pp QoQ and up 1189.6 pp YoY. The trailing four-quarter average of -408.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9% | 89.0% | 99.5% | — | — | 90.8% | — | — | — | 73.9% | 87.7% | 71.8% | 87.8% |
| — | -2.0% | — | — | — | +22.9% | — | — | — | -14.2% | -9.4% | -9.5% | -8.4% | |
| Operating Margin | -72.8% | -869.5% | 52.2% | — | — | -2059.1% | — | — | — | -1068.5% | -417.1% | -922.9% | -333.5% |
| — | +57.8% | — | — | — | -92.7% | — | — | — | -62.5% | -18868.6% | -140.0% | -166.4% | |
| Net Margin | -52.0% | -765.7% | 57.4% | — | — | -1861.6% | — | — | — | -865.5% | -341.4% | -788.0% | -300.0% |
| — | +58.9% | — | — | — | -115.1% | — | — | — | -43.8% | -6377.8% | -109.0% | -143.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10.9% | -7.9% | 11.6% | -7.8% | -6.9% | -11.6% | -4.9% | -5.7% | -5.1% | -6.0% | -5.4% | -6.7% | -6.9% |
| — | +32.3% | +336.9% | -38.2% | -36.3% | -93.5% | +9.7% | +15.4% | +26.5% | +10.8% | -1173.8% | +15.4% | -45.7% | |
| ROA | -10.2% | -7.3% | 10.7% | -7.2% | -6.5% | -11.0% | -4.7% | -5.5% | -4.9% | -5.7% | -5.2% | -6.3% | -6.3% |
| — | +34.2% | +328.8% | -32.7% | -32.1% | -91.9% | +9.5% | +12.9% | +21.8% | +5.2% | -1299.8% | +1.1% | -65.9% | |
| ROIC | -12.4% | -7.9% | 9.6% | -7.4% | -6.6% | -12.1% | -6.5% | -6.2% | -5.9% | -7.6% | -6.6% | -7.3% | -7.1% |
| — | +34.1% | +248.5% | -20.6% | -12.0% | -58.3% | +2.2% | +15.7% | +17.0% | -6.6% | -3411.8% | -0.3% | -51.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 24.3% YoY to 11.34x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.05 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| — | +199.7% | +56.7% | +1281.6% | +885.5% | +291.4% | +285.7% | -60.9% | -71.7% | -53.6% | -61.2% | -68.3% | -45.1% | |
| Debt / EBITDA | — | — | 0.25 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.34 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 | 22.93 | 17.50 | 28.42 | 19.65 | 19.37 | 19.80 | 11.53 |
| — | -24.3% | -45.7% | -29.2% | -51.0% | -23.8% | +18.4% | -11.6% | +146.4% | +68.3% | +61.1% | +322.7% | +156.6% | |
| Quick Ratio | 11.34 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 | 22.93 | 17.50 | 28.42 | 19.65 | 19.37 | 19.80 | 11.53 |
| — | -24.3% | -45.7% | -29.2% | -51.0% | -23.8% | +18.4% | -11.6% | +146.4% | +68.3% | +61.1% | +322.7% | +156.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonIDEAYA Biosciences, Inc.'s current P/E is -25.2x. The average P/E over the last 1 quarters is 5.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
IDEAYA Biosciences, Inc.'s current operating margin is -72.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IDEAYA Biosciences, Inc.'s business trajectory between earnings reports.